Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian
Helicopter crashes into field in South Yorkshire
30/10/2025
Dutch centrists D66 back in lead in election vote count, edging past far-right PVV – Europe live
30/10/2025
Crystal Palace face December fixture logjam after Carabao Cup progress
30/10/2025
Xi-Trump meeting : America has discovered that bullies can be bullied back
30/10/2025
Ministers to delegate some public appointments in attempt to cut delays
30/10/2025
Wendy & Peter Pan review – sugar-rush spectacle with an awfully big hormonal hot-crush
30/10/2025